Nuclear vitamin D receptor: Natural ligands, molecular structure-function, and transcriptional control of vital genes

Vitamin D

Volumn , Issue , 2011, Pages 137-170

  Haussler, Mark R ^a   Whitfield, G Kerr ^a   Haussler, Carol A ^a   Hsieh, Jui Cheng ^a   Jurutka, Peter W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ARIZONA STATE UNIVERSITY WEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054928794     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10008-3     Document Type: Chapter

References (264)

1. Haussler M.R., Norman A.W. Chromosomal receptor for a vitamin D metabolite. Proc. Natl. Acad. Sci. USA 1969, 62:155-162.
2. Fraser D.R., Kodicek E. Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 1970, 228:764-766.
3. Cheng J.B., Motola D.L., Mangelsdorf D.J., Russell D.W. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J. Biol. Chem. 2003, 278:38084-38093.
4. Haussler M.R., Haussler C.A., Whitfield G.K., Hsieh J.C., Thompson P.D., Barthel T.K., et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J. Steroid Biochem. Mol. Biol. 2010, 121:88-97.
5. M.B. DeMay, M.S. Kiernan, H.F. DeLuca, H.M. Kronenberg, Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 89 (1992) 8097-8101.
6. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 2010, 61:91-104.
7. Kolek O.I., Hines E.R., Jones M.D., Lesueur L.K., Lipko M.A., Kiela P.R., et al. 1{alpha},25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1036-G1042.
8. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 2008, 118:3820-3828.
9. Bikle D.D., Pillai S. Vitamin D, calcium and epidermal differentiation. Endocr. Rev. 1993, 14:3-19.
10. Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 2008, 8:685-698.
11. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr. 2002, 22:139-166.
12. 3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endocrinol. Metab. 1985, 60:960-966.
13. Bikle D. Extrarenal synthesis of 1,25-dihydroxyvitamin D and its health implications. Clin. Rev. Bone Miner. Metab. 2009, 7:114-125.
14. 3 24-hydroxylase gene. J. Biol. Chem. 1994, 269:10545-10550.
15. 3) 24-hydroxylase gene. Proc. Natl. Acad. Sci. USA 1994, 91:900-902.
16. Kim M.S., Kondo T., Takada I., Youn M.Y., Yamamoto Y., Takahashi S., et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
17. 3 in intact animals. Endocrinology 1999, 140:2224-2231.
18. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 2000, 5:173-179.
19. Jurutka P.W., Thompson P.D., Whitfield G.K., Eichhorst K.R., Hall N., Dominguez C.E., et al. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. J. Cell Biochem. 2005, 94:917-943.
20. Masuno H., Fujii S., Nakabayashi M., Ikura T., Ito N., Shimizu M., et al. Crystal structures of non-secosteroid ligands bound to vitamin D nuclear receptor. Abstracts from the 14th Workshop on Vitamin D; Brugge, Belgium, October 4-8 2009, 113.
21. Bartik L., Whitfield G.K., Kaczmarska M., Lowmiller C.L., Moffet E.W., Furmick J.K., et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J. Nutr. Biochem. 2010, 21:1153-1161.
22. Whitfield G.K., Jurutka P.W., Haussler C.A., Hsieh J.C., Barthel T.K., Jacobs E.T., et al. Nuclear vitamin D receptor: structure-function, molecular control of gene transcription, and novel bioactions. Vitamin D 2005, 219-261. Elsevier Academic Press, Oxford, UK. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
23. Hsieh J.-C., Whitfield G.K., Jurutka P.W., Haussler C.A., Thatcher M.L., Thompson P.D., et al. Two basic amino acids C-terminal of the P-box specify functional binding of the vitamin D receptor to its rat osteocalcin DNA responsive element. Endocrinology 2003, 144:5065-5080.
24. Jin C.H., Kerner S.A., Hong M.H., Pike J.W. Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol. Endocrinol. 1996, 10:945-957.
25. 3-receptor heterodimers with high affinity. Mol. Cell Endocrinol. 1995, 113:89-98.
26. Nishikawa J., Kitaura M., Matsumoto M., Imagawa M., Nishihara T. Difference and similarity of DNA sequence recognized by VDR homodimer and VDR/RXR heterodimer. Nucleic Acids Res. 1994, 22:2902-2907.
27. MacDonald P.N., Haussler C.A., Terpening C.M., Galligan M.A., Reeder M.C., Whitfield G.K., et al. Baculovirus-mediated expression of the human vitamin D receptor: functional characterization, vitamin D response element interactions, and evidence for a receptor auxiliary factor. J. Biol. Chem. 1991, 266:18808-18813.
28. Jurutka P.W., MacDonald P.N., Nakajima S., Hsieh J.-C., Thompson P.D., Whitfield G.K., et al. Isolation of baculovirus-expressed human vitamin D receptor: DNA responsive element interactions and phosphorylation of the purified receptor. J. Cell Biochem. 2002, 85:435-457.
29. van Den Bemd G.J., Jhamai M., Staal A., van Wijnen A.J., Lian J.B., Stein G.S., et al. A central dinucleotide within vitamin D response elements modulates DNA binding and transactivation by the vitamin D receptor in cellular response to natural and synthetic ligands. J. Biol. Chem. 2002, 277:14539-14546.
30. Staal A., van Wijnen A.J., Birkenhäger J.C., Pols H.A.P., Prahl J., DeLuca H., et al. Distinct conformations of vitamin D receptor/retinoid X receptor-α heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements for the osteocalcin and osteopontin genes. Mol. Endocrinol. 1996, 10:1444-1456.
31. Meyer M.B., Watanuki M., Kim S., Shevde N.K., Pike J.W. The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol. Endocrinol. 2006, 20:1447-1461.
32. Fretz J.A., Zella L.A., Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription. Mol. Endocrinol. 2006, 20:2215-2230.
33. Bishop K.A., Meyer M.B., Pike J.W. A novel distal enhancer mediates cytokine induction of mouse RANKL gene expression. Mol. Endocrinol. 2009, 23:2095-2110.
34. Barthel T.K., Mathern D.R., Whitfield G.K., Haussler C.A., Hopper H.A.T., Hsieh J.C., et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol. 2007, 103:381-388.
35. Saramaki A., Diermeier S., Kellner R., Laitinen H., Vaisanen S., Carlberg C. Cyclical chromatin looping and transcription factor association on the regulatory regions of the p21 (CDKN1A) gene in response to 1alpha,25-dihydroxyvitamin D3. J. Biol. Chem. 2009, 284:8073-8082.
36. Wang T.T., Dabbas B., Laperriere D., Bitton A.J., Soualhine H., Tavera-Mendoza L.E., et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 2010, 285:2227-2231.
37. Ohlsson R., Lobanenkov V., Klenova E. Does CTCF mediate between nuclear organization and gene expression?. Bioessays 2010, 32:37-50.
38. Jurutka P.W., Whitfield G.K., Hsieh J.-C., Thompson P.D., Haussler C.A., Haussler M.R. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Dis. 2001, 2:203-216.
39. Lyakhovich A., Aksenov N., Pennanen P., Miettinen S., Ahonen M.H., Syvala H., et al. Vitamin D induced up-regulation of keratinocyte growth factor (FGF-7/KGF) in MCF-7 human breast cancer cells. Biochem. Biophys. Res. Commun. 2000, 273:675-680.
40. 2+ influx-activating analog in osteoblastic ROS 17/2.8 cells. Steroids 2002, 67:467-470.
41. Krishnan A.V., Peehl D.M., Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell Biochem. 2003, 88:363-371.
42. Li X., Zheng W., Li Y.C. Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J. Cell Biochem. 2003, 89:709-719.
43. Swami S., Raghavachari N., Muller U.R., Bao Y.P., Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 2003, 80:49-62.
44. 3 in normal physiology. Mol. Cell Endocrinol. 1990, 72:C57-62.
45. Faraco J.H., Morrison N.A., Baker A., Shine J., Frossard P.M. ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res. 1989, 17:2150.
46. Malloy P.J., Pike J.W., Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev. 1999, 20:156-188.
47. Rut A.R., Hewison M., Kristjansson K., Luisi B., Hughes M.R., O'Riordan J.L.H. Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA-binding domain crystal structures. Clin. Endocrinol. (Oxf.) 1994, 41:581-590.
48. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci. USA 1997, 94:9831-9835.
49. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 1997, 16:391-396.
50. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., Stockmans I., Van Herck E., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc. Natl. Acad. Sci. USA 2001, 98:13324-13329.
51. Li Y.C., Amling M., Pirro A.E., Priemel M., Meuse J., Baron R., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998, 139:4391-4396.
52. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
53. Sakai Y., Demay M.B. Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 2000, 141:2043-2049.
54. Chen C.H., Sakai Y., Demay M.B. Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 2001, 142:5386-5389.
55. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
56. 3 receptor ablation alters mammary gland morphogenesis. Development 2002, 129:3067-3076.
57. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17:509-511.
58. O'Kelly J., Hisatake J., Hisatake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J. Clin. Invest. 2002, 109:1091-1099.
59. 3 receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 2002, 23:2103-2109.
60. Ellison T.I., Smith M.K., Gilliam A.C., MacDonald P.N. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J. Invest. Dermatol. 2008, 128:2508-2517.
61. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
62. Thompson P.D., Jurutka P.W., Whitfield G.K., Myskowski S.M., Eichhorst K.R., Dominguez C.E., et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 2002, 299:730-738.
63. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10:142-153.
64. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 2003, 278:46862-46868.
65. Saunders D.E., Christensen C., Wappler N.L., Schultz J.F., Lawrence W.D., Malviya V.K., et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993, 4:201-208.
66. Candeliere G.A., Jurutka P.W., Haussler M.R., St-Arnaud R. A composite element binding the vitamin D receptor, retinoid X receptor α, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c- fos promoter. Mol. Cell Biol. 1996, 16:584-592.
67. 3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 1996, 56:3570-3576.
68. Robinson-Rechavi M., Carpentier A.S., Duffraisse M., Laudet V. How many nuclear hormone receptors are there in the human genome?. Trends Genet. 2001, 17:554-556.
69. Laudet V., Auwerx J., Gustafsson J.-A., Wahli W. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97:161-163.
70. Escriva H., Delaunay F., Laudet V. Ligand binding and nuclear receptor evolution. Bioessays 2000, 22:717-727.
71. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
72. 3. Mol. Pharmacol. 2001, 60:1399-1406.
73. Araya Z., Wikvall K. 6Alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim. Biophys. Acta 1999, 1438:47-54.
74. Drocourt L., Ourlin J.C., Pascussi J.M., Maurel P., Vilarem M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 2002, 277:25125-25132.
75. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
76. Goodwin B., Redinbo M.R., Kliewer S.A. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu. Rev. Pharmacol. Toxicol. 2002, 42:1-23.
77. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92:73-82.
78. Honkakoski P., Sueyoshi T., Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann. Med. 2003, 35:172-182.
79. Guo G.L., Lambert G., Negishi M., Ward J.M., Brewer H.B., Kliewer S.A., et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 2003, 278:45062-45071.
80. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., Kliewer S.A. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002, 62:638-646.
81. Saeki M., Kurose K., Tohkin M., Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem. Pharmacol. 2008, 76:531-542.
82. R.K. Gill, S. Christakos, Identification of sequence elements in mouse calbindin-D28K gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc. Natl. Acad. Sci. USA 90 (1993) 2984-2988.
83. 3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem. Biophys. Res. Commun. 2002, 290:650-655.
84. Moore L.B., Maglich J.M., McKee D.D., Wisely B., Willson T.M., Kliewer S.A., et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 2002, 16:977-986.
85. Nagengast F.M., Grubben M.J., van Munster I.P. Role of bile acids in colorectal carcinogenesis. Eur. J. Cancer 1995, 31A:1067-1070.
86. Hamada K., Umemoto A., Kajikawa A., Seraj M.J., Monden Y. In vitro formation of DNA adducts with bile acids. Carcinogenesis 1994, 15:1911-1915.
87. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 2001, 98:3369-3374.
88. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. USA 2001, 98:3375-3380.
89. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
90. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66:S98-112.
91. Hanai H., Sugimoto K. Curcumin has bright prospects for the treatment of inflammatry bowel disease. Curr. Pharm. Des. 2009, 15:2087-2094.
92. Johnson J.J., Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007, 255:170-181.
93. de Urquiza A.M., Liu S., Sjoberg M., Zetterstrom R.H., Griffiths W., Sjovall J., et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290:2140-2144.
94. Dussault I., Forman B.M. Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins Other Lipid Mediat. 2000, 62:1-13.
95. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J. Bone Miner. Res. 2007, 22(Suppl. 2):V2-10.
96. Bartik L., Whitfield G.K., Kaczmarska M.J., Archuleta T.L., Haussler C.A., Haussler M.R., et al. Discovery of nutritionally-derived novel ligands of the vitamin D receptor: curcumin and tocotrienols 2007, The Endocrine Society, Toronto, pp Abstract P3-572.
97. Whitfield G.K., Jurutka P.W., Haussler C.A., Haussler M.R. Steroid hormone receptors: evolution, ligands and molecular basis of biologic function. J. Cell Biochem. Suppls. 1999, 32/33:110-122.
98. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001, 292:2329-2333.
99. Shaffer P.L., Gewirth D.T. Structural basis of VDR-DNA interactions on direct repeat response elements. EMBO J. 2002, 21:2242-2252.
100. Shaffer P.L., Gewirth D.T. Structural analysis of RXR-VDR interactions on DR3 DNA. J. Steroid Biochem. Mol. Biol. 2004, 89-90:215-219.
101. Cyert M.S. Regulation of nuclear localization during signaling. J. Biol. Chem. 2001, 276:20805-20808.
102. Hsieh J.-C., Shimizu Y., Minoshima S., Shimizu N., Haussler C.A., Jurutka P.W., et al. Novel nuclear localization signal between the two DNA-binding zinc fingers in the human vitamin D receptor. J. Cell Biochem. 1998, 70:94-109.
103. Luo Z., Rouvinen J., Mäenpää P.H. A peptide C-terminal to the second Zn finger of human vitamin D receptor is able to specify nuclear localization. Eur. J. Biochem. 1994, 223:381-387.
104. Prufer K., Racz A., Lin G.C., Barsony J. Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J. Biol. Chem. 2000, 275:41114-41123.
105. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell. Biol. 1998, 10:384-391.
106. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 2000, 5:289-298.
107. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995, 375:377-382.
108. Gampe R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5:545-555.
109. D.M. Tanenbaum, Y. Wang, S.P. Williams, P.B. Sigler, Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains, Proc. Natl. Acad. Sci. USA 95 (1998) 5998-6003.
110. 3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol. Endocrinol. 1996, 10:1617-1631.
111. Li M., Indra A.K., Warot X., Brocard J., Messaddeq N., Kato S., et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000, 407:633-636.
112. Feng W., Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280:1747-1749.
113. Darimont B.D., Wagner R.L., Apriletti J.W., Stallcup M.R., Kushner P.J., Baxter J.D., et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12:3343-3356.
114. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395:137-143.
115. Stehlin C., Wurtz J.M., Steinmetz A., Greiner E., Schule R., Moras D., et al. X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. EMBO J. 2001, 20:5822-5831.
116. Mi L.Z., Devarakonda S., Harp J.M., Han Q., Pellicciari R., Willson T.M., et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 2003, 11:1093-1100.
117. Malloy P.J., Xu R., Peng L., Clark P.A., Feldman D. A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol. Endocrinol. 2002, 16:2538-2546.
118. 3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding and interaction with basal transcription factor IIB, in vitro. J. Biol. Chem. 1997, 272:14592-14599.
119. 3-activated expression of the rat osteocalcin gene. Mol. Cell Biol. 1993, 13:5907-5917.
120. 3 and inhibited by 9-cis retinoic acid: evidence for allosteric receptor interactions. J. Biol. Chem. 1998, 273:8483-8491.
121. Watkins R.E., Maglich J.M., Moore L.B., Wisely G.B., Noble S.M., Davis-Searles P.R., et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003, 42:1430-1438.
122. Hoerer S., Schmid A., Heckel A., Budzinski R.M., Nar H. Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J. Mol. Biol. 2003, 334:853-861.
123. Rochel N., Tocchini-Valentini G., Egea P.F., Juntunen K., Garnier J.M., Vihko P., et al. Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur. J. Biochem. 2001, 268:971-979.
124. Malloy P.J., Hughes M.R., Pike J.W., Feldman D. Vitamin D receptor mutants and hereditary 1,25-dihydroxyvitamin D resistant rickets. Vitamin D: Gene Regulation, Structure-function Analysis and Clinical Application 1991, 116-124. Walter de Gruyter, New York. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
125. Moras D. Solution structures of nuclear receptor heterodimers RXR/RAR, RXR/VDR and RXR/PPAR on DNA. Abstracts from the 14th Workshop on Vitamin D; Brugge, Belgium, October 4-8 2009, 2.
126. 3-dependent cell-free transcription. Mol. Cell Biol. 1997, 17:1923-1937.
127. Thompson P.D., Remus L.S., Hsieh J.-C., Jurutka P.W., Whitfield G.K., Galligan M.A., et al. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. J. Mol. Endocrinol. 2001, 27:211-227.
128. Bettoun D.J., Burris T.P., Houck K.A., Buck D.W., Stayrook K.R., Khalifa B., et al. Retinoid X receptor is a non-silent major contributor to vitamin D receptor-mediated transcriptional activation. Mol. Endocrinol. 2003, 17:2320-2328.
129. Warnmark A., Treuter E., Wright A., Gustafsson J.A. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol. Endocrinol. 2003, 17:1901-1909.
130. Thompson E.B., Kumar R. DNA binding of nuclear hormone receptors influences their structure and function. Biochem. Biophys. Res. Commun. 2003, 306:1-4.
131. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474.
132. Masuyama H., Brownfield C.M., St-Arnaud R., MacDonald P.N. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol. 1997, 11:1507-1517.
133. Rachez C., Gamble M., Chang C.P., Atkins G.B., Lazar M.A., Freedman L.P. The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol. Cell Biol. 2000, 20:2718-2726.
134. Jurutka P.W., Hsieh J.-C., MacDonald P.N., Terpening C.M., Haussler C.A., Haussler M.R., et al. Phosphorylation of serine 208 in the human vitamin D receptor: the predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J. Biol. Chem. 1993, 268:6791-6799.
135. 3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry 1994, 33:4300-4311.
136. P.W. Jurutka, J.-C. Hsieh, S. Nakajima, C.A. Haussler, G.K. Whitfield, M.R. Haussler, Human vitamin D receptor phosphorylation by casein kinase II at ser-208 potentiates transcriptional activation. Proc. Natl. Acad. Sci. USA 93 (1996) 3519-3524.
137. Barletta F., Freedman L.P., Christakos S. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex. Mol. Endocrinol. 2002, 16:301-314.
138. Arriagada G., Paredes R., Olate J., van Wijnen A., Lian J.B., Stein G.S., et al. Phosphorylation at serine 208 of the 1alpha,25-dihydroxy vitamin D3 receptor modulates the interaction with transcriptional coactivators. J. Steroid Biochem. Mol. Biol. 2007, 103:425-429.
139. Pathrose P., Barmina O., Chang C.Y., McDonnell D.P., Shevde N.K., Pike J.W. Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. J. Bone Miner. Res. 2002, 17:2196-2205.
140. 3. J. Biol. Chem. 1997, 272:19027-19034.
141. Weatherman R.V., Fletterick R.J., Scanlan T.S. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 1999, 68:559-581.
142. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 1998, 393:392-396.
143. Kraichely D.M., Collins J.J., DeLisle R.K., MacDonald P.N. The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction. J. Biol. Chem. 1999, 274:14352-14358.
144. 3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 2004, 43:4101-4110.
145. Vanhooke J.L., Tadi B.P., Benning M.M., Plum L.A., DeLuca H.F. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch. Biochem. Biophys. 2007, 460:161-165.
146. Inaba Y., Nakabayashi M., Itoh T., Yoshimoto N., Ikura T., Ito N., et al. 22S-Butyl-1alpha,24R-dihydroxyvitamin D(3): recovery of vitamin D receptor agonistic activity. J. Steroid Biochem. Mol. Biol. 2010, 121:146-150.
147. Kakuda S., Okada K., Eguchi H., Takenouchi K., Hakamata W., Kurihara M.,
148. Nakabayashi M., Yamada S., Yoshimoto N., Tanaka T., Igarashi M., Ikura T., et al. Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism. J. Med. Chem. 2008, 51:5320-5329.
149. Shimizu M., Miyamoto Y., Takaku H., Matsuo M., Nakabayashi M., Masuno H., et al. 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvi tamin D3 analogs: synthesis, biological evaluation, and crystal structure. Bioorg. Med. Chem. 2008, 16:6949-6964.
150. Kurokawa R., Söderström M., Hörlein A., Halachmi S., Brown M., Rosenfeld M.G., et al. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995, 377:451-454.
151. Koszewski N.J., Ashok S., Russell J. Turning a negative into a positive: vitamin D receptor interactions with the avian parathyroid hormone response element. Mol. Endocrinol. 1999, 13:455-465.
152. Lu T.T., Repa J.J., Mangelsdorf D.J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J. Biol. Chem. 2001, 276:37735-37738.
153. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
154. Gill R.K., Atkins L.M., Hollis B.W., Bell N.H. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. Mol. Endocrinol. 1998, 12:57-65.
155. Kitagawa H., Fujiki R., Yoshimura K., Mezaki Y., Uematsu Y., Matsui D., et al. The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 2003, 113:905-917.
156. 3 and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties. Mol. Cell Biol. 1999, 19:5486-5494.
157. 3, and thyroid hormone receptors in mammalian cells. Genes Dev. 1997, 11:1381-1395.
158. Jurutka P.W., Remus L.S., Whitfield G.K., Thompson P.D., Hsieh J.-C., Zitzer H., et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 2000, 14:401-420.
159. Zhang C., Dowd D.R., Staal A., Gu C., Lian J.B., van Wijnen A.J., et al. Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J. Biol. Chem. 2003, 278:35325-35336.
160. Masuyama H., MacDonald P.N. Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J. Cell Biochem. 1998, 71:429-440.
161. Kim S., Yamazaki M., Zella L.A., Shevde N.K., Pike J.W. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell Biol. 2006, 26:6469-6486.
162. Tolhuis B., Palstra R.J., Splinter E., Grosveld F., de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol. Cell 2002, 10:1453-1465.
163. Spilianakis C.G., Flavell R.A. Long-range intrachromosomal interactions in the T helper type 2 cytokine locus. Nature Immunol. 2004, 5:1017-1027.
164. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
165. Wang Q., Carroll J.S., Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 2005, 19:631-642.
166. Zella L.A., Kim S., Shevde N.K., Pike J.W. Enhancers located in the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 2007, 103:435-439.
167. Xue Y., Karaplis A.C., Hendy G.N., Goltzman D., Miao D. Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles. Endocrinology 2006, 147:4801-4810.
168. Noda M., Nagao M., Hanyu R., Miyai K., Ezura Y. Bone fracture and the healing mechanisms. Molecular bases of fracture healing. Clin. Calcium 2009, 19:634-640.
169. Weissen-Plenz G., Nitschke Y., Rutsch F. Mechanisms of arterial calcification: spotlight on the inhibitors. Adv. Clin. Chem. 2008, 46:263-293.
170. Wang K.X., Denhardt D.T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008, 19:333-345.
171. Bianco S.D., Peng J.B., Takanaga H., Suzuki Y., Crescenzi A., Kos C.H., et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J. Bone Miner. Res. 2007, 22:274-285.
172. Garland C., Shekelle R.B., Barrett-Connor E., Criqui M.H., Rossof A.H., Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985, 1:307-309.
173. Milat F., Ng K.W. Is Wnt signalling the final common pathway leading to bone formation?. Mol. Cell Endocrinol. 2009, 310:52-62.
174. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
175. Yadav V.K., Oury F., Suda N., Liu Z.W., Gao X.B., Confavreux C., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
176. Markose E.R., Stein J.L., Stein G.S., Lian J.B. Vitamin D-mediated modifications in protein-DNA interactions at two promoter elements of the osteocalcin gene. Proc. Natl. Acad. Sci. USA 1990, 87:1701-1705.
177. 3. Proc. Natl. Acad. Sci. USA 1990, 87:369-373.
178. Terpening C.M., Haussler C.A., Jurutka P.W., Galligan M.A., Komm B.S., Haussler M.R. The vitamin D-responsive element in the rat bone Gla protein gene is an imperfect direct repeat that cooperates with other cis-elements in 1,25-dihydroxyvitamin D3-mediated transcriptional activation. Mol. Endocrinol. 1991, 5:373-385.
179. Ozono K., Liao J., Kerner S.A., Scott R.A., Pike J.W. The vitamin D-responsive element in the human osteocalcin gene: association with a nuclear proto-oncogene enhancer. J. Biol. Chem. 1990, 265:21881-21888.
180. Poundarik A., Gambino C., Gundberg C., Vashishth D. Osteocalcin - a determinant of bone toughness. J. Bone. Miner. Res. 2009, 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=dad3 da21-5679-47be-8094-96626d7e516f.
181. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
182. Keisala T., Minasyan A., Lou Y.R., Zou J., Kalueff A.V., Pyykko I., et al. Premature aging in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 2009, 115:91-97.
183. Masuda S., Byford V., Arabian A., Sakai Y., Demay M.B., St-Arnaud R., et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005, 146:825-834.
184. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 1986, 78:1296-1301.
185. Fukagawa M., Kazama J.J. FGF23: its role in renal bone disease. Pediatr. Nephrol. 2006, 21:1802-1806.
186. Yuan B., Takaiwa M., Clemens T.L., Feng J.Q., Kumar R., Rowe P.S., et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J. Clin. Invest. 2008, 118:722-734.
187. Fukumoto S. Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism. Rinsho. Byori. 2007, 55:555-559.
188. 3 downregulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J. Biol. Chem. 2004, 279:46406-46414.
189. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
190. Hesse M., Frohlich L.F., Zeitz U., Lanske B., Erben R.G. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 2007, 26:75-84.
191. Renkema K.Y., Alexander R.T., Bindels R.J., Hoenderop J.G. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann. Med. 2008, 40:82-91.
192. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009, 5:611-619.
193. Fukuda T., Kanomata K., Nojima J., Urakawa I., Suzawa T., Imada M., et al. FGF23 induces expression of two isoforms of NAB2, which are corepressors of Egr-1. Biochem. Biophys. Res. Commun. 2007, 353:147-151.
194. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
195. Kuro-o M. Klotho and aging. Biochim. Biophys. Acta 2009, 1790:1049-1058.
196. Wang Y., Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009, 54:810-817.
197. Jin T., George Fantus I., Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal. 2008, 20:1697-1704.
198. Kohler E.M., Chandra S.H., Behrens J., Schneikert J. Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours. Hum. Mol. Genet. 2009, 18:213-226.
199. Egan J.B., Thompson P.A., Vitanov M.V., Bartik L., Jacobs E.T., Haussler M.R., et al. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. Mol. Carcinog. 2010, 49:337-352.
200. 3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001, 154:369-387.
201. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 2002, 157:303-314.
202. Shahnazari M., Yao W., Corr M., Lane N.E. Targeting the Wnt signaling pathway to augment bone formation. Curr. Osteoporos. Rep. 2008, 6:142-148.
203. Huelsken J., Vogel R., Erdmann B., Cotsarelis G., Birchmeier W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001, 105:533-545.
204. Cianferotti L., Cox M., Skorija K., Demay M.B. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl. Acad. Sci. USA 2007, 104:9428-9433.
205. Beaudoin G.M., Sisk J.M., Coulombe P.A., Thompson C.C. Hairless triggers reactivation of hair growth by promoting Wnt signaling. Proc. Natl. Acad. Sci. USA 2005, 102:14653-14658.
206. Lintern K.B., Guidato S., Rowe A., Saldanha J.W., Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 2009, 284:23159-23168.
207. Bikle D., Schauber J., Gallo R., Elias P., Uchida Y., Oda Y. Differential regulation of epidermal function by VDR coactivators. J. Steroid Biochem. Mol. Biol. 2010, 121:308-313.
208. Thompson C.C., Sisk J.M., Beaudoin G.M. Hairless and Wnt signaling: allies in epithelial stem cell differentiation. Cell Cycle 2006, 5:1913-1917.
209. Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 2009, 94:26-34.
210. Hsieh J.-C., Sisk J.M., Jurutka P.W., Haussler C.A., Slater S.A., Haussler M.R., et al. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J. Biol. Chem. 2003, 278:38665-38674.
211. Zarach J.M., Beaudoin G.M., Coulombe P.A., Thompson C.C. The co-repressor hairless has a role in epithelial cell differentiation in the skin. Development 2004, 131:4189-4200.
212. Potter G.B., Zarach J.M., Sisk J.M., Thompson C.C. The thyroid hormone-regulated corepressor hairless associates with histone deacetylases in neonatal rat brain. Mol. Endocrinol. 2002, 16:2547-2560.
213. Hsieh J.C., Slater S.A., Whitfield G.K., Dawson J.L., Hsieh G., Sheedy C., et al. Analysis of hairless corepressor mutants to characterize molecular cooperation with the vitamin D receptor in promoting the mammalian hair cycle. J. Cell Biochem. 2010, 110:671-686.
214. Yamamoto Y., Memezawa A., Takagi K., Ochiai E., Shindo M., Kato S. A tissue-specific function by unliganded VDR. Abstracts from the 14th Workshop on Vitamin D; Brugge, Belgium, October 4-8 2009, 66.
215. Suzuki T., Tazoe H., Taguchi K., Koyama Y., Ichikawa H., Hayakawa S., et al. DNA microarray analysis of changes in gene expression induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 cells. Biomed. Res. 2006, 27:99-109.
216. Logsdon C.D., Fuentes M.K., Huang E.H., Arumugam T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 2007, 7:777-789.
217. 3-mediated transcriptional repression. Mol. Endocrinol. 1996, 10:672-681.
218. Cho Y.M., Woodard G.L., Dunbar M., Gocken T., Jimenez J.A., Foley J. Hair-cycle-dependent expression of parathyroid hormone-related protein and its type I receptor: evidence for regulation at the anagen to catagen transition. J. Invest. Dermatol. 2003, 120:715-727.
219. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 1998, 13:325-349.
220. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
221. Bikle D.D., Oda Y., Xie Z. Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J. Steroid. Biochem. Mol. Biol. 2004, 89-90:355-360.
222. Norman A.W., Frankel J.B., Heldt A.M., Grodsky G.M. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209:823-825.
223. Clemens T.L., Zhou X.Y., Pike J.W., Haussler M.R., Sloviter R.S. 1,25-Dihydroxyvitamin D receptor and vitamin D-dependent calcium binding protein in rat brain: comparative immunocytochemical localization. Vitamin D: Chemical, Biochemical and Clinical Update 1985, 95-96. Walter de Gruyter, Berlin. A.W. Norman, K. Schaefer, H.-G. Grigoleit, D.V. Herrath (Eds.).
224. Kalueff A.V., Keisala T., Minasyan A., Kuuslahti M., Miettinen S., Tuohimaa P. Behavioural anomalies in mice evoked by "Tokyo" disruption of the Vitamin D receptor gene. Neurosci. Res. 2006, 54. 254-260.
225. 3. Proc. Natl. Acad. Sci. USA 1995, 92:10990-10994.
226. Cohen-Lahav M., Shany S., Tobvin D., Chaimovitz C., Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol. Dial. Transplant. 2006, 21:889-897.
227. Canaff L., Hendy G.N. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem. 2002, 277:30337-30350.
228. Echchgadda I., Song C.S., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 2004, 65:720-729.
229. Richards J.B., Valdes A.M., Gardner J.P., Paximadas D., Kimura M., Nessa A., et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am. J. of Clin. Nutr. 2007, 86:1420-1425.
230. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65:7917-7925.
231. Audo I., Darjatmoko S.R., Schlamp C.L., Lokken J.M., Lindstrom M.J., Albert D.M., et al. Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:4192-4199.
232. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 2002, 16:1243-1256.
233. Kallay E., Pietschmann P., Toyokuni S., Bajna E., Hahn P., Mazzucco K., et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001, 22:1429-1435.
234. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346:476-483.
235. Guilliams T.G. Homocysteine - a risk factor for vascular diseases: guidelines for the clinical practice. JANA 2004, 7:11-24.
236. Kriebitzsch C., Verlinden L., Eelen G., Marchal K., De Moor B., Beullens I., et al. Regulation of cystathionine beta synthase by 1alpha,25-dihydroxyvitamin D3, Abstracts from the 14th Workshop on Vitamin D; Brugge, Belgium, October 4-8 2009, 10.
237. Eelen G., Gysemans C., Verlinden L., Gijsbers R., Beullens I., Van Camp M., et al. Induction of FOXO3a by 1,25D in MC3T3E1 cells mediates resistance to oxidative stress. Abstracts from the 14th Workshop on Vitamin D; Brugge, Belgium, October 4-8 2009, 60.
238. Lin M., Beal M. The oxidative damage theory of aging. Clin. Neurosci. Res. 2003, 2:305-315.
239. Lian J.B., Shalhoub V., Aslam F., Frenkel B., Green J., Hamrah M., et al. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 1997, 138:2117-2127.
240. S.A. Kerner, R.A. Scott, J.W. Pike, Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc. Natl. Acad. Sci. USA 86 (1989) 4455-4459.
241. 3 enhancement of mouse secreted phosphoprotein 1 (Spp-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. USA 1990, 87:9995-9999.
242. Pike J.W., Meyer M.B., Watanuki M., Kim S., Zella L.A., Fretz J.A., et al. Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor. J. Steroid. Biochem. Mol. Biol. 2007, 103:389-395.
243. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp. Cell Res. 2002, 274:323-333.
244. 3. J. Biol. Chem. 1993, 268:27371-27380.
245. Quelo I., Machuca I., Jurdic P. Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene. J. Biol. Chem. 1998, 273:10638-10646.
246. 3 receptor. Mol. Endocrinol. 1996, 10:206-215.
247. 3. Identification of a vitamin D-responsive element in the human NAPi-3 gene. J. Biol. Chem. 1998, 273:14575-14581.
248. Barwick J.L., Quattrochi L.C., Mills A.S., Potenza C., Tukey R.H., Guzelian P.S. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol. Pharmacol. 1996, 50:10-16.
249. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
250. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 2004, 18:1109-1119.
251. 3. J. Invest. Dermatol. 2002, 119:1109-1113.
252. Kikuchi R., Sobue S., Murakami M., Ito H., Kimura A., Iwasaki T., et al. Mechanism of vitamin D3-induced transcription of phospholipase D1 in HaCat human keratinocytes. FEBS Lett. 2007, 581:1800-1804.
253. Shirakawa A.K., Nagakubo D., Hieshima K., Nakayama T., Jin Z., Yoshie O. 1,25-Dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J. Immunol. 2008, 180:2786-2795.
254. Cardus A., Panizo S., Encinas M., Dolcet X., Gallego C., Aldea M., et al. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204:85-89.
255. Malloy P.J., Peng L., Wang J., Feldman D. Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Endocrinology 2009, 150:1580-1587.
256. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1?1501 is regulated by vitamin D. PLoS Genetics 2009, e1000369.
257. Gombart A.F., Borregaard N., Koeffler H.P. Human catidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005, 19:1067-1077.
258. Wang X., Wang T.T., White J.H., Studzinski G.P. Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. Oncogene 2006, 25:7078-7085.
259. Wang X., Wang T.T., White J.H., Studzinski G.P. Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation. Exp. Cell Res. 2007, 313:3034-3045.
260. Lee S., Lee D.K., Choi E., Lee J.W. Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol. Endocrinol. 2005, 19:399-408.
261. Eloranta J.J., Zair Z.M., Hiller C., Hausler S., Stieger B., Kullak-Ublick G.A. Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol. Pharmacol. 2009, 76:1062-1071.
262. Jmol: an open-source Java viewer for chemical structures in 3D. http://www.jmol.org/.
263. Fuchs E., Merrill B.J., Jamora C., DasGupta R. At the roots of a never-ending cycle. Dev. Cell 2001, 1:13-25.
264. Peters E.M., Foitzik K., Paus R., Ray S., Holick M.F. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J. Invest. Dermatol. 2001, 117:173-178.